
    <html>
    <head><title>BHC.TO — algorithm buy 10d</title>
<style>
body {
  font-family: Arial, sans-serif;
  margin: 20px;
}
.container {
  display: grid;
  grid-template-columns: 50% 50%;
  grid-template-rows: auto auto;
  gap: 20px;
}
img {
  width: 100%;
  height: auto;
  max-height: 400px;
  border: 1px solid #ccc;
  object-fit: contain;
}

.cell {
  padding: 10px;
}
.table-scroll {
  max-height: 400px;
  overflow-y: auto;
  border: 1px solid #aaa;
}
table {
  width: 100%;
  border-collapse: collapse;
}
th, td {
  border: 1px solid #aaa;
  padding: 5px;
  text-align: left;
  font-size: 14px;
}
.negative {
  background: linear-gradient(to right, #ffdddd, white);
}
.positive {
  background: linear-gradient(to right, white, #ddffdd);
}
.pos-light  { background: #e6ffe6; }  
.pos-mid    { background: #99ff99; }  
.pos-strong { background: #33cc33; }   

.neg-light  { background: #ffe6e6; }   
.neg-mid    { background: #ff9999; }   
.neg-strong { background: #ff3333; }   

h2 { border-bottom: 2px solid #444; }
<script>
function toggleText(id) {
  const moreText = document.getElementById(id);
  const btn = document.getElementById(id + "_btn");

  if (moreText.style.display === "none") {
    moreText.style.display = "inline";
    btn.innerText = " Show less";
  } else {
    moreText.style.display = "none";
    btn.innerText = " Show more";
  }
}
</script>
</style>
</head>
    <body>
    <h2><span style='color:#1e66f5; font-weight:900; margin-right:10px;'>quarterly earnings d</span> BHC.TO <span style='margin-left:8px; padding:2px 6px; border:1px solid #0a0; border-radius:6px; background:#eaffea; color:#0a0; font-weight:700;'>algorithm buy 10d</span> 
        <span style='font-weight:normal; font-size: 18px;'>(111d - Guidance update)</span>
        <span style='color:green; font-weight:bold; font-size: 20px;'> 63D POS</span>
        <a href='https://finance.yahoo.com/chart/BHC.TO?interval=1mo' target='_blank'>Yahoo</a>
        <span style='font-weight:600;'>  —  — now: 10.06  — ATR_low: 9.17 (cta 9 days)</span>
    </h2>

    <div class="container">
        <div class="cell"><div style='display:flex; gap:10px; align-items:flex-start'>  <div style='flex:0 0 50%'><a href='https://vosorin.github.io/100__2025_06_public/RAPORT/C_ZOOM_BHC.TO_NEWS.png' target='_blank'>    <img src='C_ZOOM_BHC.TO_NEWS.png' alt='C_ZOOM_BHC.TO_NEWS.png'></a></div>  <div style='flex:0 0 50%'><a href='https://vosorin.github.io/100__2025_06_public/RAPORT/C_BHC.TO_BAND.jpg' target='_blank'>    <img src='C_BHC.TO_BAND.jpg' alt='C_BHC.TO_BAND.jpg'></a></div></div></div>
        <div class="cell"><div style='display:flex; gap:10px; align-items:flex-start'>  <div style='flex:0 0 50%'><a href='https://vosorin.github.io/100__2025_06_public/RAPORT/B_ZOOM_BHC.TO_ALL.jpg' target='_blank'>    <img src='B_ZOOM_BHC.TO_ALL.jpg' alt='B_ZOOM_BHC.TO_ALL.jpg'></a></div>  <div style='flex:0 0 50%'><a href='https://vosorin.github.io/100__2025_06_public/RAPORT/B_BHC.TO_BAND.jpg' target='_blank'>    <img src='B_BHC.TO_BAND.jpg' alt='B_BHC.TO_BAND.jpg'></a></div></div></div>
        <div class="cell"><div style='display:flex;gap:10px;align-items:flex-start'><a href="https://vosorin.github.io/100__2025_06_public/RAPORT/A_BHC.TO_63d_pos_ZOOM.png" target="_blank"><img src="A_BHC.TO_63d_pos_ZOOM.png" alt="A_BHC.TO_63d_pos_ZOOM.png"></a><a href="https://vosorin.github.io/100__2025_06_public/RAPORT/A_BHC.TO_63d_pos.jpg" target="_blank"><img src="A_BHC.TO_63d_pos.jpg" alt="A_BHC.TO_63d_pos.jpg"></a></div></div>
        <div class="cell"><div class='table-scroll'><table><tr><th>Date</th><th>Score</th><th>AMR</th><th>Type</th><th>Summary</th><th>Links</th></tr><tr class='pos-light'><td>2025-09-11</td><td>0.35</td><td></td><td>Guidance update</td><td>0.35 local feel              __   BHC.TO __    -> i:0.35<-                      <br><br>FEELING: total score 0.35 Here's a breakdown of the scoring: Insider Buying (Paulson & others): +0.3 - Significant insider buying, especially by a well-known investor like Paulson, is a strong positive signal. This suggests confidence in the company's future prospects. Revenue Exceeding Expectations: +0.1 - While not as impactful as earnings, exceeding revenue expectations is a mildly positive sign. Analyst Upgrade: +0.05 - A single analyst upgrade is a low-impact event. Earnings Miss: -0.05 - Missing earnings estimates is a negative, but the revenue beat partially offsets this. RBC stake reduction: -0.05 - A reduction in stake by a major institution is a negative signal. High Debt-to-Equity Ratio: -0.05 - The high debt-to-equity ratio is a concern, introducing risk and limiting potential upside. Note: The backward-looking data (past year trends) and promotional language are ignored, as per the instructions. --- <br> - Bausch Health is experiencing mixed signals. While Royal Bank of Canada reduced its stake, several other institutions and insiders are increasing their positions, notably Director John Paulson's significant purchase. Recent earnings missed estimates, but revenue exceeded expectations. Analyst upgrades suggest a potential upside, but caution is warranted given the high debt-to-equity ratio. <br><br>*** REZUMAT *** - RBC reduced its Bausch Health stake by 24.8% during Q1. - SBI Securities increased holdings by 244.2%, owning 4,230 shares. - Cary Street Partners, Caitong, Wealthquest, and HSBC bought new stakes. - Director John Paulson bought 34.72M shares at $9.00/share, increasing ownership by 96.35%. - Insiders acquired 42.53M shares valued at $360.43M last quarter. - BHC stock traded down $0.06 to $7.16 on Wednesday. - Company has a debt-to-equity ratio of 141.90. - Q3 earnings were $0.90/share, missing the $0.97 estimate. - Revenue was $2.57B, exceeding the $2.47B expectation. - Wall Street Zen upgraded BHC from "hold" to "buy" on August 2nd. - Analysts forecast 4.41 EPS for the current year.   (gemma3:12b-it-q4_K_M on 2025-09-11 23:41:57)</td><td><a href='https://www.marketbeat.com/instant-alerts/filing-bausch-health-cos-inc-bhc-shares-sold-by-royal-bank-of-canada-2025-09-05/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-09-11</td><td>0.30</td><td></td><td>Merger announcement</td><td>0.3 local feel              __   BHC.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Reasoning: Mergers/acquisitions: The acquisition of DURECT is potentially accretive. The $63M price tag plus potential $350M milestones suggests a strategic move. The Breakthrough Therapy Designation for larsucosterol is a significant positive, indicating potential for accelerated approval and revenue generation. This contributes a score of +0.3. FDA or Canada Health decisions: The Breakthrough Therapy Designation is a positive signal from the FDA, contributing +0.4. However, the need to monitor clinical trial progress and regulatory approval timelines introduces some uncertainty, which slightly reduces the overall impact. Delisting: DURECT's delisting from Nasdaq is a consequence of the acquisition and has a neutral to slightly negative impact, but the overall positive impact of the acquisition outweighs this. Backward-looking data/promotional language: The news focuses on future potential and strategic moves, minimizing the impact of backward-looking data. --- <br> - Bausch Health's acquisition of DURECT for $63M, plus potential $350M milestones, adds a promising liver disease treatment (larsucosterol) with Breakthrough Therapy Designation. Investors should monitor clinical trial progress and regulatory approval timelines for potential upside. <br><br>*** REZUMAT *** - Bausch Health completed acquisition of DURECT for $63M on Sept 11, 2025. - Acquisition includes potential $350M milestone payments. - Larsucosterol, an AH treatment, received FDA Breakthrough Therapy Designation. - Larsucosterol targets DNA methylation in AH patients. - Phase 3 clinical trials are planned to evaluate larsucosterol's efficacy. - DURECT will be delisted from Nasdaq following the merger. - Bausch Health expects to be a globally integrated healthcare company.   (gemma3:12b-it-q4_K_M on 2025-09-11 23:40:25)</td><td><a href='https://www.stocktitan.net/news/BHC/bausch-health-completes-acquisition-of-durect-corporation-expanding-gps1d6ax0mvf.html' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-09-11</td><td>-0.35</td><td></td><td>Debt restructuring / renegotiation</td><td>-0.35 local feel              __   BHC.TO __    -> i:0.35<-                      <br><br>FEELING: total score -0.35 Individual contributor breakdown: Debt load/Financial Stability: -0.25 (Significant debt load and concerns about financial stability are major negatives. The high debt-to-EBITDA ratio, weak interest cover, and relatively weak free cash flow all contribute to this. The "warning signs" mentioned by analysts amplify this concern.) EBIT Growth: +0.1 (8.0% EBIT growth is a slightly positive signal, but it's overshadowed by the debt concerns. It's a small offset to the negative sentiment.) Free Cash Flow: -0.05 (Free cash flow being "weaker than expected" adds to the negative sentiment.) Analyst Warnings: -0.05 (The mention of "warning signs" from analysts reinforces the negative outlook.) --- <br> - Bausch Health Companies carries a significant debt load, raising concerns about its financial stability. While recent EBIT growth is positive, the high debt-to-EBITDA ratio, weak interest cover, and relatively weak free cash flow suggest a risky investment profile. Investors should proceed with caution. <br><br>*** REZUMAT *** - - BHC has US$21.7b in debt (June 2025), with US$1.73b in cash, resulting in US$20.0b net debt. - - Total liabilities exceed cash and receivables by US$23.2b. - - Interest cover is 1.3x, indicating potential difficulty in servicing debt. - - Net debt to EBITDA ratio is 6.4, signaling a heavy debt load. - - EBIT grew 8.0% in the last year, slowly reducing debt relative to earnings. - - Free cash flow is 27% of EBIT, considered weaker than expected. - - Analysts highlight 2 warning signs for BHC, one of which cannot be ignored.   (gemma3:12b-it-q4_K_M on 2025-09-11 23:25:24)</td><td><a href='https://news.futunn.com/en/post/61997576/these-4-measures-indicate-that-bausch-health-companies-nyse-bhc' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-09-11</td><td>0.30</td><td></td><td>Merger announcement</td><td>0.3 local feel              __   BHC.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Reasoning: Mergers/acquisitions: The acquisition of DURECT is the most significant event. The acquisition cost seems reasonable, and the potential milestone payments ($350 million) represent a substantial upside. The acquisition of a late-stage treatment with Breakthrough Therapy Designation for a significant disease (alcohol-associated hepatitis) is generally accretive, contributing a +0.3 score. FDA or Canada Health decisions: The Breakthrough Therapy Designation is a positive signal from the FDA, suggesting potential for accelerated approval. This adds +0.1. Product launches: Larsucosterol represents a new product with strong market potential, adding +0.1. The news contains forward-looking information regarding clinical trials and regulatory approval timelines, which are important for future performance. --- <br> - Bausch Health's acquisition of DURECT adds a promising late-stage liver disease treatment (larsucosterol) with Breakthrough Therapy Designation for alcohol-associated hepatitis. While milestone payments offer potential upside, investors should monitor clinical trial progress and regulatory approval timelines. <br><br>*** REZUMAT *** - Bausch Health completed acquisition of DURECT on Sept 11, 2025. - Acquisition cost: $63 million upfront, potential $350 million milestone payments. - Larsucosterol, for alcohol-associated hepatitis, is the key asset gained. - Larsucosterol has FDA Breakthrough Therapy Designation. - Phase 3 clinical trial planned to evaluate larsucosterol's efficacy. - DURECT will be a wholly owned subsidiary of Bausch Health. - DURECT stock will cease trading on Nasdaq.   (gemma3:12b-it-q4_K_M on 2025-09-11 23:22:32)</td><td><a href='https://www.prnewswire.com/news-releases/bausch-health-completes-acquisition-of-durect-corporation-expanding-late-stage-liver-disease-portfolio-302553904.html' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-09-09</td><td>0.30</td><td></td><td>quarterly earnings</td><td>0.3 local feel              __   BHC.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Individual contributor breakdown: Debt restructuring / renegotiation: +0.2 (The $250M debt refinancing and $40M credit facility are positive developments, simplifying the capital structure and enhancing liquidity. However, the reliance on sustained growth introduces a conditional element.) Guidance updates: +0.1 (Projected revenue of $586.7M by 2028 and earnings of $209.0M can be considered a forward-looking guidance, albeit with a significant growth requirement.) Fair value estimates: Very low absolute score value (Analysts' estimates are considered, but have a low impact unless there is a clear consensus.) Product performance: Very low absolute score value (Mention of VEVYE, IHEEZO, and TRIESENCE is backward-looking and doesn't inherently signal a change in outlook.) Growth requirement: -0.1 (The need for 37.1% yearly revenue growth is a significant hurdle and introduces risk.) --- <br> - Harrow's debt refinancing improves liquidity and provides flexibility, but hinges on sustained growth of key products like VEVYE, IHEEZO, and TRIESENCE. Investors should monitor upcoming results and competitive pressures closely. <br><br>*** REZUMAT *** - Harrow completed a $250M debt refinancing and secured a $40M credit facility. - Refinancing simplifies capital structure and enhances liquidity. - Flagship product performance (VEVYE, IHEEZO, TRIESENCE) remains key. - Q2 2025 revenue: $63.74M with net profitability. - Projected revenue: $586.7M by 2028; earnings: $209.0M. - Fair value estimates range from $51.17 to $247.60. - Growth requires 37.1% yearly revenue growth.   (gemma3:12b-it-q4_K_M on 2025-09-09 22:34:01)</td><td><a href='https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrow/harrow/news/how-harrows-250m-debt-refinancing-and-new-credit-facility-ha' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-09-05</td><td>0.30</td><td></td><td>Guidance updates</td><td>0.3 local feel              __   BHC.TO __    -> i:0.3<-                      <br><br>FEELING: total score +0.3 Reasoning: Revenue Growth Expectations (+0.4): The news highlights expected revenue growth of 42% annually for the next 3 years, significantly outpacing the industry average of 26%. This is a positive forward-looking indicator. Recent Revenue Declines (-0.1): The recent revenue declines (-24% last year, -12% over 3 years) are a negative factor, but the expectation of future growth somewhat mitigates this. High P/S Ratio (-0.1): The high P/S ratio (13.9x) is flagged as a caution, suggesting potential overvaluation. While concerning, it's linked to the expected growth, so it's not purely negative. The overall sentiment leans positive due to the strong growth expectations, but the recent performance and valuation concerns prevent a higher score. --- <br> - Aquestive Therapeutics (AQST) stock has surged, driven by expectations of significant revenue growth (42% annually for the next 3 years) outpacing the industry average. However, the high P/S ratio (13.9x) warrants caution and further investigation into the company's revenue performance and future prospects. <br><br>*** REZUMAT *** - AQST stock up 28% in the last month, 20% YTD. - High P/S ratio of 13.9x compared to industry average (below 4.9x). - Recent revenue declining: -24% last year, -12% over 3 years. - Analysts forecast 42% annual revenue growth for next 3 years. - Industry revenue growth forecast at 26% annually. - High P/S justified by expected strong future revenue growth.   (gemma3:12b-it-q4_K_M on 2025-09-06 13:13:11)</td><td><a href='https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aqst/aquestive-therapeutics/news/aquestive-therapeutics-inc-nasdaqaqst-stocks-shoot-up-28-but' target='_blank'>Link</a></td></tr><tr class='pos-mid'><td>2025-09-05</td><td>0.70</td><td></td><td>quarterly earnings</td><td>0.70 GPT4 / 0.55 local feel              __   BHC.TO __    -> i:0.7<-                      <br><br>FEELING: 0.7 --- <br> - Bausch Health's Thermage technology reaching 5 million treatments, coupled with strong Q2 2025 earnings (EPS $0.40 vs. $0.04 expected, revenue $2.53B vs. $2.48B) and CABTREO expansion, suggest positive momentum for the company. <br><br>*** REZUMAT *** - Bausch Health's Thermage technology surpasses 5 million treatments globally. - Company market cap: $2.7 billion, with 70% gross margins. - Thermage uses radiofrequency energy for skin tightening and smoothing. - Bausch Health maintains a "GREAT" financial health score. - Q2 2025 EPS: $0.40, beating estimates of $0.04. - Q2 2025 Revenue: $2.53 billion, exceeding $2.48 billion expectations. - CABTREO acne treatment now available in Quebec and Saskatchewan. - Year-over-year revenue increase: 7.1%. - Company considered undervalued according to InvestingPro metrics.   <br> <br>-- GPT4: +0.7, Buy, Strong earnings and product expansion boost outlook.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-09-06 13:11:56)</td><td><a href='https://www.investing.com/news/company-news/bausch-healths-thermage-technology-surpasses-5-million-treatments-93CH-4226733' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-09-05</td><td>0.20</td><td></td><td>product launches</td><td>0.2 local feel              __   BHC.TO __    -> i:0.2<-                      <br><br>FEELING: total score 0.2 Reasoning: The news highlights strong demand for Bausch Health's aesthetic business through the success of Solta Medical's Thermage treatments. This falls under product launches (specifically, continued strong performance of an existing product) and can be interpreted as a positive signal for future revenue generation. While not a brand new launch, sustained high demand suggests ongoing market acceptance and potential for further growth. This warrants a slightly positive score of 0.2. The fact that it's a milestone (5 million treatments) adds a bit of weight to the positive impact. --- <br> - Bausch Health's Solta Medical division achieved a significant milestone with 5 million Thermage treatments, indicating strong demand for their non-surgical skin tightening system. This positive development could boost investor confidence. <br><br>*** REZUMAT *** - Solta Medical, part of Bausch Health, reached 5 million Thermage treatments. - Thermage is a non-surgical skin tightening system. - News highlights strong demand for Bausch Health's aesthetic business.   (gemma3:12b-it-q4_K_M on 2025-09-06 13:10:17)</td><td><a href='https://finance.yahoo.com/news/bausch-healths-aesthetic-business-solta-120200701.html' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-09-05</td><td>0.20</td><td></td><td>Product launch</td><td>0.2 local feel              __   BHC.TO __    -> i:0.2<-                      <br><br>FEELING: total score 0.2 Reasoning: The news highlights a significant milestone (5 million Thermage treatments) and suggests continued growth potential for Bausch Health's Solta Medical division. This falls under product launches and growth potential, indicating a positive outlook. The planned investment in R&D is also a mildly positive signal. While the disclaimer about forward-looking statements is present, the core message is positive. The score is not higher because the news doesn's explicitly mention financial impact or accretive factors. --- <br> - Bausch Health's Solta Medical division achieved a significant milestone with 5 million Thermage skin tightening treatments, demonstrating strong demand and trust in their technology. This reinforces their position in the aesthetics market and suggests continued growth potential. <br><br>*** REZUMAT *** - Bausch Health's Solta Medical reached 5 million Thermage skin tightening treatments. - Thermage utilizes monopolar radiofrequency for skin tightening and collagen production. - The system is indicated for wrinkle treatment and is the only non-invasive option for eyelids. - Solta Medical plans to invest in R&D and clinical evidence for Thermage. - Bausch Health is a global pharmaceutical company with a focus on aesthetics. - Forward-looking statements are subject to risks and uncertainties.   (gemma3:12b-it-q4_K_M on 2025-09-06 21:37:35)</td><td><a href='https://www.stocktitan.net/news/BHC/bausch-health-s-aesthetic-business-solta-medical-surpasses-milestone-gjzjo6rkt6u3.html' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-09-01</td><td>0.30</td><td></td><td>tender offer extension</td><td>0.3 local feel              __   BHC.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Reasoning: The news primarily revolves around the acquisition of Durect. Extending the tender offer suggests a desire to finalize the acquisition, which is generally positive. An accretive merger/acquisition receives a score of +0.3 to +0.4. Since the news indicates a continued effort to finalize the acquisition, it leans towards a slightly positive sentiment. The lack of specifics about the extended offer prevents a higher score. --- <br> - Bausch Health has extended its tender offer for Durect, likely to secure full acquisition. Investors should monitor the final outcome and potential integration impacts. <br><br>*** REZUMAT *** - Bausch Health extended Durect tender offer. - Extension allows for continued acquisition efforts. - Details of the extended offer not specified. - Acquisition aims to finalize Durect ownership.   (gemma3:12b-it-q4_K_M on 2025-09-04 15:57:03)</td><td><a href='https://www.msn.com/en-us/money/companies/bausch-health-announces-extension-of-durect-tender-offer/ar-AA1Lg2Gb?apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-31</td><td>0.35</td><td></td><td>Insider activity</td><td>0.35 local feel              __   BHC.TO __    -> i:0.35<-                      <br><br>FEELING: total score 0.35 Here's a breakdown of the scoring: Insider buying (John Paulson): +0.3 - A substantial purchase by a known investor signals confidence and is a positive sign. Institutional Investor Activity (Overall Increase): +0.1 - Several institutions increasing their stakes is generally positive, indicating belief in the company's future. Missed Earnings: -0.1 - Missing earnings estimates is a negative, but the impact is lessened by the revenue beat. Revenue Beat: +0.05 - Beating revenue estimates is a slight positive. FY 2025 EPS Guidance: +0.05 - Setting guidance is a positive sign, indicating forward-looking visibility. Analyst Upgrade (Wall Street Zen): +0.05 - A rating upgrade is a minor positive. Debt-to-equity ratio: -0.05 - A high debt-to-equity ratio is a concern, but not a major negative given the other positives. Note: The significant insider buying and institutional stake increases outweigh the missed earnings and debt concerns, leading to a slightly positive overall score. --- <br> - Bausch Health Cos is experiencing significant institutional investor activity, with several increasing their stakes. Insider John Paulson's substantial purchase signals confidence, though the company missed earnings estimates and has a concerning debt-to-equity ratio. Monitor earnings and debt management. <br><br>*** REZUMAT *** - Deutsche Bank sold 2,099,217 BHC shares, a 98.6% reduction in Q1. - Vanguard increased stake by 0.5%, owning 11,746,480 shares ($76.15M). - Dimensional Fund Advisors increased stake by 3.0%, owning 3,113,107 shares ($25.09M). - Compass Rose Asset Management increased stake by 366.7%, owning 2,100,000 shares ($16.93M). - Private Management Group increased stake by 13.8%, owning 1,439,426 shares ($9.31M). - Charles Schwab Investment Management increased stake by 4.5%, owning 1,341,999 shares ($8.70M). - Insider John Paulson bought 34,721,118 shares at $9.00/share ($312.5M). - Insiders bought 44,316,834 shares worth $369.63M in last 90 days. - BHC stock up 3.6%, opened at $7.41 on Friday. - Debt-to-equity ratio: 141.90, current ratio: 1.31, quick ratio: 0.98. - Missed Q3 earnings by $0.07, reported $0.90 EPS vs. $0.97 estimate. - Revenue: $2.57B, beating consensus estimate of $2.47B. - FY 2025 EPS guidance set. - Analysts expect $4.41 EPS for the current fiscal year. - Wall Street Zen raised rating to Buy. Average target price: $9.00.   (gemma3:12b-it-q4_K_M on 2025-09-04 19:47:04)</td><td><a href='https://www.defenseworld.net/2025/08/31/deutsche-bank-ag-sells-2099217-shares-of-bausch-health-cos-inc-bhc.html' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-29</td><td>0.35</td><td></td><td>quarterly earnings</td><td>0.35 local feel              __   BHC.TO __    -> i:0.35<-                      <br><br>FEELING: total score 0.35 Breakdown: quarterly or annual results: Adjusted EPS beat estimates significantly (+0.2), but missed target (-0.1). Net effect: +0.1 debt reduction: $900 million debt repaid and $7.9 billion debt refinancing completed (+0.2) acquisitions: Acquired DURECT Corporation (+0.1) guidance updates: Full-year revenue projected between $4.95 billion and $5.1 billion (+0.1) product launches: Cabtreo acne treatment now available in Canadian provinces (+0.05) analyst meetings: Zacks Rank #4 (Sell) rating (-0.1) - mitigated by "potential for recovery exists" (+0.05) Rationale: The news presents a mixed bag. The strong Q2 2025 results (revenue and EBITDA growth) and significant debt reduction are positive. The acquisition signals a strategic focus. However, the EPS miss and "Sell" rating from Zacks temper the enthusiasm. The forward-looking revenue guidance is a positive contributor. The overall tone suggests cautious optimism, justifying a slightly positive score. --- <br> - Bausch Health demonstrates resilience with strong Q2 2025 results and strategic initiatives. While regulatory risks exist, the company's focus on innovation, debt reduction, and niche markets positions it for long-term growth. Investors should monitor regulatory impacts but consider BHC a potentially rewarding opportunity. <br><br>*** REZUMAT *** - Revenue increased 5% YoY to $2.53 billion in Q2 2025. - Adjusted EBITDA rose 10% to $842 million. - Salix segment revenue up 12% to $627 million, driven by Xifaxan. - Solta Medical segment surged 25% YoY. - Adjusted EPS of $0.90 beat estimates by 900%, but missed target by 7.22%. - $900 million debt repaid, $7.9 billion debt refinancing completed. - Acquired DURECT Corporation for hepatology focus. - Rifaximin SSD Phase 3 results expected in early 2026. - Cabtreo acne treatment now available in Canadian provinces. - Full-year revenue projected between $4.95 billion and $5.1 billion. - Zacks Rank #4 (Sell) rating, but potential for recovery exists.   (gemma3:12b-it-q4_K_M on 2025-09-04 23:33:39)</td><td><a href='https://www.ainvest.com/news/bausch-health-bhc-sustaining-momentum-post-earnings-strategic-deep-dive-2508/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-28</td><td>0.20</td><td></td><td>Merger announcement</td><td>0.20 GPT4 / 0.40 local feel              __   BHC.TO __    -> i:0.4<-                     **   ** 2025-09-10 **   <br><br>** 2025-09-10  Merger announcement ***<br>FEELING: 0.2 --- <br> - Durect's stock surge is driven by the Bausch Health merger and FDA designations, despite Q2 losses. The extended tender offer provides more time for shareholders, and the potential for milestone payments is significant. Monitor the merger's progress and larsucosterol's development. <br><br>*** REZUMAT *** - DRRX stock up 270% due to merger news and cost management. - Q2 revenue decreased to $447,000, net loss $2.3 million. - Bausch Health extends tender offer until September 10, 2025. - Offer price remains at $1.75 per share, potential $350M milestone payments. - Larsucosterol received FDA Fast Track & Breakthrough Therapy designations. - Major shareholder Scott Asen purchased 5,917 shares valued at $11,301. - Merger may impact Durect's operations and stakeholder interests.   <br> <br>-- GPT4: 0.2, Hold, Merger progress and FDA designations may boost BHC.TO slightly.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-09-05 05:35:18)</td><td><a href='https://www.ainvest.com/news/durect-stock-sees-surge-bausch-health-merger-fda-designations-2508/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-21</td><td>0.30</td><td></td><td>Guidance update</td><td>0.30 GPT4 / 0.45 local feel              __   BHC.TO __    -> i:0.3<-                      <br><br>FEELING: 0.3 --- <br> - Bausch Health is experiencing significant institutional interest, with multiple funds increasing their positions. Insider buying is substantial, but the stock faces challenges with negative returns and a high debt-to-equity ratio. Investors should monitor earnings and guidance closely. <br><br>*** REZUMAT *** - SNB trimmed BHC position by 1.1% in Q1, owning 537,660 shares. - Maple Rock Capital Partners increased BHC stake by 156.7%, owning 5,300,000 shares. - Compass Rose Asset Management grew BHC position by 366.7%, owning 2,100,000 shares. - Renaissance Technologies increased BHC stake by 1,761.5%, owning 495,172 shares. - Vestal Point Capital acquired a new $2,015,000 BHC position. - D. E. Shaw grew BHC stake by 84.1%, owning 544,707 shares. - Insider John Paulson bought 34,721,118 shares at $9.00/share. - Insiders bought 44,316,834 shares worth $369,628,560 in last quarter. - 78.65% of BHC stock is owned by institutional investors. - BHC stock opened at $7.5950, 52-week range: $4.25-$9.85. - Debt-to-equity ratio: 141.90, current ratio: 1.31, quick ratio: 0.98. - Q3 EPS: $0.90, missing estimate by $0.07, revenue: $2.57B. - RBC raised target price to $10.00, Wall Street Zen upgraded to Buy. - Consensus target price: $9.00, rating: Hold.   <br> <br>-- GPT4: 0.3, Hold, Institutional interest and insider buying could boost BHC.TO, but high debt limits upside.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-21 23:05:08)</td><td><a href='https://www.defenseworld.net/2025/08/21/swiss-national-bank-has-3-49-million-stock-position-in-bausch-health-cos-inc-bhc.html' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-20</td><td>0.30</td><td></td><td>nan</td><td>0.30 GPT4 / 0.30 local feel              __   BHC.TO __    -> i:0.3<-                      <br><br>FEELING: 0.3 --- <br> - Bausch Health's stock surged 45% due to significant insider buying. This signals confidence from within the company, potentially indicating a positive outlook for investors. Monitor further developments. <br><br>*** REZUMAT *** - Bausch Health (BHC) stock up 45%. - Surge driven by substantial insider buying. - Indicates confidence from company insiders.   <br> <br>-- GPT4: +0.3, Hold, Insider buying suggests confidence; watch for sustained trends.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-20 22:37:12)</td><td><a href='https://www.msn.com/en-us/money/companies/bausch-health-bhc-climbs-45-on-insider-buying/ar-AA1KKhIQ' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-20</td><td>0.20</td><td></td><td>Debt restructuring / renegotiation</td><td>0.2 local feel              __   BHC.TO __    -> i:0.2<-                      <br><br>FEELING: total score 0.2 Reasoning: The news primarily focuses on debt reduction through the redemption of notes. This falls under debt restructuring / renegotiation. A move towards debt reduction is generally viewed favorably, suggesting improved financial health and reduced risk. Therefore, a slightly positive score of +0.2 is assigned. The fact that the notes are due in 2026 suggests a proactive measure rather than a sign of immediate distress, further supporting the positive, albeit modest, assessment. --- <br> - Bausch Health is using available funds to redeem $602 million in notes due in 2026, indicating a move towards debt reduction and potentially strengthening its financial position. <br><br>*** REZUMAT *** - $602 million in outstanding notes to be redeemed. - Notes due in 2026. - Move towards debt reduction for Bausch Health.   (gemma3:12b-it-q4_K_M on 2025-08-20 22:36:30)</td><td><a href='https://www.msn.com/en-us/money/companies/bausch-health-to-redeem-602m-of-outstanding-notes-due-2026/ar-AA1Jro86?apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-08-20</td><td>-0.20</td><td></td><td>Insider activity</td><td>-0.20 GPT4 / 0.35 local feel              __   BHC.TO __    -> i:0.2<-                      <br><br>FEELING: -0.2 --- <br> - BHC sees insider buying and Icahn selling, impacting the stock. BLCO lags in valuation, while Pepsi shows potential with new investor interest. Monitor debt levels and valuation discrepancies for informed decisions. <br><br>*** REZUMAT *** - BHC jumped 45% last week due to insider block trade at $9.00. - John Paulson bought $312.5 million (35 million shares) of BHC. - Carl Icahn sold 34.7 million BHC shares on August 14. - BLCO valuation lags behind peer Alcon (ALC). - BHC faces significant debt repayment challenges. - Pepsi (PEP) is a neglected stock with potential for growth. - Nomura bought over 4 million PEP shares in Q2. - Barclays is a new investor in Pepsi (PEP).   <br> <br>-- GPT4: -0.2, Hold, Insider buying boosts BHC but debt challenges persist.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-20 22:23:58)</td><td><a href='https://www.baystreet.ca/stockstowatch/21460/Why-BHC-BLCO-and-Pepsi-are-Under-the-Radar' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-19</td><td>0.20</td><td></td><td>nan</td><td>0.2 local feel              __   BHC.TO __    -> i:0.2<-                      <br><br>FEELING: total score +0.2 Reasoning: The primary driver of the score is the endorsement from John Paulson. While not a guaranteed positive, a renowned value investor taking a significant stake in a company is generally viewed favorably by the market. This suggests potential for future positive developments and can attract other investors. Here's a breakdown of how the events list was applied: Analyst meetings: While not a formal analyst meeting, Paulson's investment acts as a strong signal, similar to a positive initiation of coverage. This contributes a +0.1. Management changes: Paulson hiring Alan Greenspan as an advisor is a positive signal, contributing +0.1. Other factors: The size of Paulson & Co.'s assets and Paulson's track record are supportive details, but don't directly impact the score. The score is not higher because it's an endorsement, not a concrete financial event like a merger or earnings surprise. --- <br> - John Paulson, a renowned value investor, recently purchased shares in Bausch Health, signaling confidence in the company's potential. This endorsement from a historically successful investor could positively influence stock performance. <br><br>*** REZUMAT *** - John Paulson, founder of Paulson & Co., purchased Bausch Health shares. - Paulson & Co. manages $36 billion in assets. - Paulson is known for anticipating market movements, notably the 2008 crisis. - Paulson Credit fund achieved 590% performance in 2007. - Paulson has hired Alan Greenspan as an advisor.   (gemma3:12b-it-q4_K_M on 2025-08-19 19:35:49)</td><td><a href='https://www.marketscreener.com/news/bausch-health-pick-of-the-week-at-smart-insider-following-non-executive-chair-paulson-s-stock-purcha-ce7c51dddb8cf123' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-18</td><td>0.30</td><td></td><td>Management changes</td><td>0.30 GPT4 / 0.30 local feel              __   BHC.TO __    -> i:0.3<-                     **   ** 2025-01-01 **   <br><br>** 2025-01-01  Management changes ***<br>FEELING: 0.3 --- <br> - Bausch Health's governance shift, marked by Icahn's exit and Paulson's entry, signals a move towards stability and long-term value creation. Investors should monitor debt reduction progress and Bausch + Lomb's performance, but the company's renewed focus on operational discipline presents a compelling investment opportunity. <br><br>*** REZUMAT *** - Icahn Group exited Bausch Health's board in 2025, ending activist-driven governance. - Paulson Capital Inc. now holds 19.13% stake, emphasizing operational optimization. - Bausch Health's SRP introduced in April 2025, triggered a 12% stock price surge. - Board expanded from 10 to 12 members, adding expertise in executive compensation & regulatory compliance. - Q2 2025 revenue: $2.53 billion, adjusted EBITDA up 6% to $842 million. - $900 million debt reduction plan announced in July 2025. - $4.4 billion bond offering used to refinance obligations. - Bausch + Lomb contributed $1.28 billion in Q2 2025 revenue. - 2025 AGM showed preference for Paulson with 8.43 million votes secured.   <br> <br>-- GPT4: +0.3, Hold, Governance shift suggests stability; debt reduction and operational focus are positive signals.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-18 22:44:44)</td><td><a href='https://www.ainvest.com/news/strategic-governance-shifts-shareholder-bausch-lomb-bausch-health-era-stability-confidence-2508/' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-08-18</td><td>-0.20</td><td></td><td>Management changes</td><td>-0.2 local feel              __   BHC.TO __    -> i:0.2<-                      <br><br>FEELING: total score -0.2 Reasoning: The news primarily revolves around the resignation of two board members (Brett Icahn and Gary Hu). This falls under management changes. Sudden departures, especially from prominent figures like Brett Icahn, are generally viewed negatively as they introduce uncertainty. This warrants a score of -0.2. The article highlights the need to monitor the reasons behind the resignations and potential impact on the company's strategy, further reinforcing the negative sentiment due to the uncertainty introduced. There's no indication of a positive replacement or a clear explanation for the departures, so the score remains negative. --- <br> - The resignation of Brett Icahn and Gary Hu from Bausch + Lomb's board introduces uncertainty. Investors should monitor the reasons behind the resignations and potential impact on the company's strategy. <br><br>*** REZUMAT *** - Brett Icahn and Gary Hu resigned from Bausch + Lomb's board. - Resignations occurred on August 18, 2025. - Article is reserved for members.   (gemma3:12b-it-q4_K_M on 2025-08-18 22:41:12)</td><td><a href='https://www.marketscreener.com/news/bausch-lomb-says-brett-icahn-and-gary-hu-have-resigned-from-its-board-ce7c51dcdd89f125' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-18</td><td>0.30</td><td></td><td>Management changes</td><td>0.30 GPT4 / 0.30 local feel              __   BHC.TO __    -> i:0.5<-                     **   ** 2025-08-31 **   <br><br>** 2025-08-31  Management changes ***<br>FEELING: 0.3 --- <br> - The departure of Icahn and Paulson's governance shift at Bausch Health signal a move towards long-term stability and operational efficiency. Investors with a long-term perspective should consider this a potentially positive development, but careful monitoring of debt levels and R&D progress remains crucial. <br><br>*** REZUMAT *** - Icahn Group representatives (Brett Icahn, Steven Miller) resigned from Bausch Health's board in August 2025. - Paulson Capital acquired 34.7 million shares, triggering a governance reset due to ownership thresholds. - Paulson's ownership now stands at 19.13%, emphasizing board independence and strategic continuity. - Michael Goettler & Sandra Leung appointed to board, addressing historical governance weaknesses. - Paulson's strategy focuses on debt reduction, R&D optimization, and shareholder returns. - LKQ Corp restructuring resulted in a 40% stock price increase over two years. - Realogy Corp restructuring involved $494 million debt exchange for convertible notes. - Bausch Health stock surged 12% after a $900 million debt reduction plan. - Shareholder Rights Plan (SRP) limits ownership to 20% per shareholder. - Q2 2025 Bausch + Lomb revenue: $1.28 billion, adjusted EBITDA: $842 million (6% YoY growth). - Potential sale of Bausch + Lomb rejected, favoring internal growth. - Bausch Health's debt offering is $4.4 billion.   <br> <br>-- GPT4: +0.3, Monitor closely, Governance shift and debt focus may stabilize long-term growth.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-18 22:34:07)</td><td><a href='https://www.ainvest.com/news/corporate-governance-shareholder-influence-bausch-lomb-era-stability-strategic-realignment-2508/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-18</td><td>0.30</td><td></td><td>Management changes</td><td>0.30 GPT4 / 0.35 local feel              __   BHC.TO __    -> i:0.5<-                     **   ** 2025-08-31 **   <br><br>** 2025-08-31  Management changes ***<br>FEELING: 0.3 --- <br> - Bausch + Lomb's shift away from activist investor influence, spearheaded by Paulson Capital, signals a move towards stable, long-term value creation. Investors should monitor debt reduction, R&D investment, and shareholder returns, recognizing the potential for sustainable growth alongside inherent risks. <br><br>*** REZUMAT *** - Paulson Capital acquired Icahn's 34% stake, triggering a governance realignment. - Brett Icahn and Steven Miller resigned from the board, ending an activist era. - Paulson now holds 19.13% stake, emphasizing operational optimization. - Michael Goettler and Sandra Leung joined the board, bringing pharmaceutical expertise. - $900 million debt reduction plan funded by a $4.4 billion bond offering. - Stock price surged 12% following the Shareholder Rights Plan (SRP) announcement. - Bausch + Lomb contributed $1.28 billion in Q2 2025 revenues, with 6% adjusted EBITDA growth. - The board is focused on integrating Bausch + Lomb, avoiding spin-offs. - Paulson received fewer withheld votes at the 2025 AGM, showing shareholder alignment. - Key metrics to watch: Debt-to-Equity Ratio, R&D Expenditure, Shareholder Returns.   <br> <br>-- GPT4: +0.3, Hold, Governance shift and debt reduction boost long-term stability.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-18 22:33:02)</td><td><a href='https://www.ainvest.com/news/bausch-lomb-post-icahn-restructuring-era-governance-shareholder-2508/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-18</td><td>0.30</td><td></td><td>quarterly earnings</td><td>0.30 GPT4 / 0.40 local feel              __   BHC.TO __    -> i:0.3<-                      <br><br>FEELING: 0.3 --- <br> - InvestingPro's AI-picked stock list has delivered exceptional returns, with three stocks rallying over 45% in just 15 days. This highlights the potential of AI-driven stock selection, though past performance doesn't guarantee future success. Consider the limited-time summer sale for potential exposure. <br><br>*** REZUMAT *** - AI-picked stock list yielded three stocks up over 45% in 15 days. - ViaSat Inc (VSAT) soared +63.45% MTD after earnings beat. - One stock jumped +45% on a +59.59% premium takeover offer. - Third stock up +46.06% MTD due to Paulson Capital's stake. - Bausch Health (BHC) was picked for "Growth Momentum at Value Price." - BHC reported Q2 2025 EPS of $0.40 (vs. $0.04 expected). - BHC revenue increased 8.5% LTM and EBITDA grew 5.4%. - 16 stocks in August list gained over 10% MTD. - Warren Buffetts mystery stock up +27.86% MTD. - August picks have an 84% hit rate, 100% in positive territory. - ProPicks AI Tech Titans up +120% since November 2023 launch. - Tech Titans outperformed S&P 500 by 81.22% since launch. - AI refreshes stock picks monthly with up to 20 selections. - Backtesting suggests long-term holding for wealth generation.   <br> <br>-- GPT4: +0.3, Hold, BHC's growth momentum and strong Q2 earnings boost potential.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-18 22:30:25)</td><td><a href='https://ca.investing.com/news/stock-market-news/it-did-it-again-yet-a-third-aipicked-stock-is-up-45-this-month-alone-4163761' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-18</td><td>0.30</td><td></td><td>Management changes</td><td>0.30 GPT4 / 0.35 local feel              __   BHC.TO __    -> i:0.3<-                      <br><br>FEELING: 0.3 --- <br> - Icahn's departure signals the end of a specific agreement, but Bausch + Lomb's strong recent performance and positive earnings surprise, coupled with increased stake by Paulson Capital, suggest continued investor confidence. <br><br>*** REZUMAT *** - Icahn representatives (Brett Icahn, Gary Hu) resigned from Bausch + Lomb board. - Agreement ended due to Icahn group's ownership stake falling below threshold. - Bausch + Lomb stock up 25% in the past week. - Bausch Health reported Q2 EPS of $0.40, exceeding $0.04 estimate. - Revenue reached $2.53 billion, a 5% increase year-over-year. - Paulson Capital increased stake in Bausch Health to approximately 19.13%. - Paulson acquired 34.7 million shares previously held by Icahn.   <br> <br>-- GPT4: +0.3, Hold, Strong performance and investor confidence offset Icahn's exit.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-18 22:29:11)</td><td><a href='https://www.investing.com/news/company-news/icahn-representatives-resign-from-bausch--lomb-board-as-agreement-ends-93CH-4198685' target='_blank'>Link</a></td></tr><tr class='neg-mid'><td>2025-08-18</td><td>-0.70</td><td></td><td>guidance update</td><td>-0.70 GPT4 / -0.30 local feel              __   BHC.TO __    -> i:0.7<-                      <br><br>FEELING: -0.7 --- <br> - Bausch + Lomb's stock is facing headwinds due to a guidance cut and the enVista recall. Investors should anticipate continued volatility and closely monitor the company's response and recall progress. <br><br>*** REZUMAT *** - Bausch + Lomb stock is down. - Guidance has been cut by the company. - Recall of enVista lenses is ongoing. - Recall impacts financial outlook negatively.   <br> <br>-- GPT4: -0.7, Hold, Guidance cut and recall weigh heavily on outlook.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-18 22:25:44)</td><td><a href='https://www.msn.com/en-us/money/markets/bausch-lomb-drops-after-guidance-cut-amid-envista-recall/ar-AA1DVXHf?ocid=finance-verthp-feeds&apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-18</td><td>0.30</td><td></td><td>Management changes</td><td>0.30 GPT4 / 0.30 local feel              __   BHC.TO __    -> i:0.3<-                      <br><br>FEELING: 0.3 --- <br> - Bausch Health (BHC) saw a significant boost after Paulson Capital increased its stake, signaling confidence in the company's turnaround. Monitor global developments and resource prices for potential TSX direction. <br><br>*** REZUMAT *** - TSX Composite Index slightly declined to 27,905 on August 18. - Weekly change: +0.5%, year-to-date gains near +13%. - Bausch Health (BHC) jumped 11% to $11.52 due to Paulson Capital's increased stake. - Paulson Capital now holds nearly 19.1% of BHC's outstanding shares. - Brett Icahn and Steven Miller resigned from Bausch Health's board. - BHC stock surged 41% in August. - MDA Space, SSR Mining, and Northland Power also gained over 4%. - Bird Construction, TerraVest, and ATS were among the worst performers. - Enbridge, Cenovus, Barrick, Canadian Natural Resources, and Manulife were most active. - Precious metals up, crude oil and natural gas slightly down.   <br> <br>-- GPT4: +0.3, Hold, Paulson's increased stake boosts confidence in BHC's turnaround potential.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-18 22:38:33)</td><td><a href='https://www.fool.ca/2025/08/18/tsx-today-what-to-watch-for-in-stocks-on-monday-august-18/' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-08-16</td><td>-0.20</td><td></td><td>guidance updates</td><td>-0.2 local feel              __   BHC.TO __    -> i:0.2<-                      <br><br>FEELING: total score -0.2 Reasoning: Here's a breakdown of the scoring based on the provided news and the defined events: Stock Performance (Positive, but tempered): The news highlights significant stock gains (30% in 30 days, 46% annually). This would normally be a positive signal (+0.2). However, the low P/S ratio and underwhelming revenue outlook temper this enthusiasm. Revenue Growth (Negative): The core issue is the slower revenue growth (0.9% annually) compared to the industry (26% annually). This is a significant negative signal (-0.3). Analysts' concerns about the revenue outlook reinforce this. P/S Ratio (Negative): The low P/S ratio (0.3x) suggests caution and undervaluation, which is a negative signal (-0.1). Backward-Looking Data: The mentions of last year's and three-year revenue growth are largely irrelevant for a forward-looking assessment and receive a very low score. Analyst Sentiment: Analyst concerns are mentioned, but there's no clear consensus, so the impact is minimal. Calculation: +0.2 (Stock Performance) -0.3 (Revenue Growth) -0.1 (Low P/S Ratio) Total: -0.2 --- <br> - Bausch Health's stock has seen significant gains (30% in 30 days, 46% annually), but its low P/S ratio (0.3x) suggests caution. Revenue growth needs to improve substantially to justify the current valuation, as analysts predict weaker performance compared to industry growth (26% vs. 0.9%). <br><br>*** REZUMAT *** - BHC stock up 30% in last 30 days, 46% annually. - P/S ratio is 0.3x, significantly lower than industry median. - Revenue growth slower than most companies recently. - Last year's revenue increased by 7.1%. - Three-year revenue growth: 20%. - Projected revenue growth: 0.9% annually for next 3 years. - Industry revenue growth predicted at 26% annually. - Analysts cite underwhelming revenue outlook as a key factor.   (gemma3:12b-it-q4_K_M on 2025-08-16 19:23:45)</td><td><a href='https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhc/bausch-health-companies/news/improved-revenues-required-before-bausch-health-companies-in' target='_blank'>Link</a></td></tr><tr class='pos-mid'><td>2025-08-15</td><td>0.70</td><td></td><td>quarterly earnings</td><td>0.70 GPT4 / 0.65 local feel              __   BHC.TO __    -> i:0.7<-                      <br><br>FEELING: 0.7 --- <br> - Bausch Health's strong Q2 results, boosted by an FDA breakthrough designation and strategic acquisitions like DURECT, signal a positive outlook. Debt reduction plans and a bolstered balance sheet further strengthen their position, making it a potentially attractive investment for those seeking growth in the healthcare sector. <br><br>*** REZUMAT *** - BHC stock up 8.06% following FDA breakthrough designation and strong Q2 results. - Q2 EPS climbed to 40 cents, revenue surpassed $2.53B, exceeding expectations. - Acquisition of DURECT targets liver disease therapeutics, strengthening hepatology portfolio. - $900M debt reduction planned, including redemption of $602M Senior Notes. - Gross margin at 85.6%, EBITDAMargin teased at 31.3%, reflecting operational efficiency. - Assets at $27.26B, liabilities at $27.1B, indicating fiscal discipline. - DURECT acquisition and debt reduction boost investor confidence. - Board expertise bolstered with Michael Goettler and Sandra Leung. - Focus on long-term debt engagements and potential dividend maneuvers.   <br> <br>-- GPT4: +0.7, Buy, Strong Q2 results and strategic moves boost confidence.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-16 02:33:51)</td><td><a href='https://stockstotrade.com/news/bausch-health-companies-inc-bhc-news-2025_08_15/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-15</td><td>0.30</td><td></td><td>Management changes</td><td>0.30 GPT4 / 0.40 local feel              __   BHC.TO __    -> i:0.3<-                      <br><br>FEELING: 0.3 --- <br> - Paulson's increased stake and Icahn's reduced position significantly impact Bausch Health. The departure of Icahn-affiliated directors and Paulson's confidence signal potential for value creation, but investors should monitor developments closely. <br><br>*** REZUMAT *** - Bausch Health stock up 11.3% on Paulson's increased stake. - Paulson now owns approximately 19.13% of Bausch Health shares. - Icahn Group's stake reduced below a threshold, triggering agreement termination. - Brett M. Icahn and Steven D. Miller resigned from the Board. - Paulson expresses confidence in Bausch Health's value and prospects. - No agreement exists between Paulson, Icahn, or Bausch Health.   <br> <br>-- GPT4: +0.3, Hold, Paulson's increased stake signals confidence; monitor for stability.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-16 03:42:10)</td><td><a href='https://www.investing.com/news/stock-market-news/bausch-health-stock-soars-after-paulson-increases-stake-93CH-4195992' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-15</td><td>0.30</td><td></td><td>nan</td><td>0.30 GPT4 / 0.30 local feel              __   BHC.TO __    -> i:0.3<-                      <br><br>FEELING: 0.3 --- <br> - Significant insider buying, particularly from Paulson and Jain, suggests confidence in the company's future. However, substantial selling by key executives warrants caution and further investigation before making investment decisions. <br><br>*** REZUMAT *** - August 14, 2025: Summary of US stock insider activity. - Jacob McDonough: Bought 3,149 shares ($34.85-$42.92), total $125,359. - John Paulson: Bought 34,721,118 shares at $9.0, totaling ~$312.5 million. - Coliseum Capital: Purchased 1,537,852 shares ($5.15-$5.46), total ~$8.1 million. - Clint Coghill: Bought 350,000 shares ($3.6929-$3.8888), total ~$1.33 million. - Vivek Jain: Bought 21,929 shares ($112.1165-$112.9232), total ~$2.47 million. - Andy Nemeth: Sold 25,000 shares at $110.0-$113.3854, total ~$2.77 million. - Mark Widmar: Sold 26,308 shares ($181.78-$189.91), total ~$5.15 million. - D. James Bidzos: Sold 8,900 shares ($262.8028-$267.4286), total ~$2.39 million. - Ernest Garcia II: Sold 141,985 shares, total value ~$61.9 million.   <br> <br>-- GPT4: 0.3, Hold, Insider buying suggests confidence but executive selling advises caution.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-16 02:51:14)</td><td><a href='https://ca.investing.com/news/stock-market-news/thursdays-insider-activity-top-buys-and-sells-in-us-stocks-93CH-4162371' target='_blank'>Link</a></td></tr><tr class='neg-light'><td>2025-08-15</td><td>-0.20</td><td></td><td>management changes</td><td>-0.2 local feel              __   BHC.TO __    -> i:0.2<-                      <br><br>FEELING: total score -0.2 Reasoning: The news primarily concerns a management change ("The resignation of Brett M. Icahn and Steven D. Miller from Bausch Health's board"). Sudden departures, especially of significant figures like Icahn and Miller, are generally viewed negatively as they introduce uncertainty. This triggers a score of -0.2. The article mentions monitoring the impact on strategy and future direction, highlighting the potential for disruption, which reinforces the negative sentiment. The fact that the resignations occurred recently (August 15, 2025) suggests immediate impact. --- <br> - The resignation of Brett M. Icahn and Steven D. Miller from Bausch Health's board signals a significant shift in corporate governance. Investors should monitor how this impacts the company's strategy and future direction. <br><br>*** REZUMAT *** - Icahn and Miller resigned from Bausch Health's board. - Resignations occurred on August 15, 2025. - News reported by MarketScreener. - Article is reserved for members.   (gemma3:12b-it-q4_K_M on 2025-08-16 03:11:24)</td><td><a href='https://www.marketscreener.com/news/bausch-health-brief-brett-m-icahn-and-steven-d-miller-have-resigned-from-the-board-of-directors-ce7c51ded18fff27' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-15</td><td>0.30</td><td></td><td>Management changes</td><td>0.30 GPT4 / 0.30 local feel              __   BHC.TO __    -> i:0.3<-                      <br><br>FEELING: 0.3 --- <br> - The Chairperson's increased shareholding and board changes signal confidence in Bausch Health's future, potentially attracting investors. Monitor the impact of these changes on the company's performance. <br><br>*** REZUMAT *** - Chairperson increased shareholding, indicating confidence. - Board changes announced. - Stock price up +11.05% (market close). - 5-day change: +3.47%. - Year-to-date change: +45.04%. - Market close: 2025-08-15.   <br> <br>-- GPT4: +0.3, Hold, Increased shareholding and board changes boost confidence.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-16 03:17:22)</td><td><a href='https://www.marketscreener.com/news/bausch-health-brief-announcing-increase-in-shareholding-by-its-chairperson-of-the-board-and-board-c-ce7c51ded18ff12c' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-15</td><td>0.30</td><td></td><td>Insider buying</td><td>0.30 GPT4 / 0.45 local feel              __   BHC.TO __    -> i:0.3<-                      <br><br>FEELING: 0.3 --- <br> - Bausch Health's significant insider buying, particularly by John Paulson, coupled with recent strong earnings and a focus on digital transformation, suggests a compelling value opportunity. Investors should proceed with cautious optimism, monitoring regulatory shifts and potential policy changes. <br><br>*** REZUMAT *** - John Paulson acquired over 70 million BHC shares, totaling $312.49 million. - Insider buying spans from $5.05 to $9.00, indicating a long-term strategy. - BHC reported adjusted EPS of $0.40 (vs. $0.04 expected) and $2.53 billion revenue. - Stock surged 30% to $7.51 following earnings and insider activity. - U.S. IRA projects a 31% revenue decline for pharma by 2039. - PwC pharma index returned 7.6% (2018-2024), lagging S&P 500 (15%). - BHC focuses on cost optimization, portfolio diversification, and digital transformation. - Catalyst Pharmaceuticals saw insider sales, while Oric had mixed signals. - Bausch Health's market cap is $2.77 billion, with a fair value of $7.50. - Potential risks include policy shifts under the Trump administration.   <br> <br>-- GPT4: +0.3, Hold, Insider buying and strong earnings suggest potential growth, but regulatory risks remain.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-16 03:21:49)</td><td><a href='https://www.ainvest.com/news/bausch-health-insider-purchase-strategic-indicator-investors-2508/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-15</td><td>0.30</td><td></td><td>nan</td><td>0.30 GPT4 / 0.30 local feel              __   BHC.TO __    -> i:0.3<-                      <br><br>FEELING: 0.3 --- <br> - Paulson's increased stake signals confidence in Bausch Health, potentially attracting other investors and boosting the stock price. Monitor further developments and analyst commentary. <br><br>*** REZUMAT *** - Paulson increased his stake in Bausch Health. - Stock price soared following the news. - Signals confidence from a prominent investor. - No specific stake size or percentage disclosed.   <br> <br>-- GPT4: +0.3, monitor closely, Increased stake by Paulson signals confidence but lacks specific details.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-16 14:13:17)</td><td><a href='https://ca.investing.com/news/stock-market-news/bausch-health-stock-soars-after-paulson-increases-stake-93CH-4162971' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-15</td><td>0.30</td><td></td><td>Insider purchase</td><td>0.30 GPT4 / 0.30 local feel              __   BHC.TO __    -> i:0.3<-                      <br><br>FEELING: 0.3 --- <br> - Bausch Health's stock is experiencing a positive reaction to a significant $300 million insider purchase, signaling confidence in the company's future prospects. Investors should monitor further developments. <br><br>*** REZUMAT *** - Bausch Health stock price increased. - Insider purchase valued at $300 million. - Signals confidence from company insiders.   <br> <br>-- GPT4: +0.3, Hold, Insider purchase boosts confidence; watch for sustained impact.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-16 03:44:18)</td><td><a href='https://www.msn.com/en-us/money/companies/bausch-health-rises-after-300m-worth-insider-purchase/ar-AA1KASKT?ocid=finance-verthp-feeds' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-15</td><td>0.30</td><td></td><td>Management changes</td><td>0.30 GPT4 / 0.40 local feel              __   BHC.TO __    -> i:0.3<-                      <br><br>FEELING: 0.3 --- <br> - Bausch Health is undergoing a significant transformation, balancing shareholder influence with strengthened governance and strategic board additions. While risks remain, the company's focus on debt reduction and operational improvements suggests a potential for long-term value creation, making it worth a reassessment for investors. <br><br>*** REZUMAT *** - Bausch Health (BHC) faces a pivotal moment due to shareholder and board changes. - Carl Icahn holds 34% economic stake (9.4% direct, 24.6% swaps maturing in 2028). - Shareholder Rights Plan (SRP) activated in April 2025 limits Icahn's control. - All 10 directors re-elected in May 2025, with Brett M. Icahn receiving 199 million votes. - Board expanded to 12 members, adding Michael Goettler (Viatris) and Sandra Leung (Bristol Myers Squibb). - Company announced a $900 million debt reduction plan in July 2025. - $4.4 billion bond offering to refinance obligations. - Stock surged 12% after SRP announcement in April 2025. - Acne treatment Cabtreo and Canadian pharmaceutical alliance are de-risking revenue. - Key metrics to monitor: Debt-to-Equity Ratio, R&D Expenditure, Shareholder Returns.   <br> <br>-- GPT4: 0.3, Hold, Governance changes and debt reduction signal stability; positive long-term outlook.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-16 13:55:53)</td><td><a href='https://www.ainvest.com/news/bausch-health-shareholder-board-shake-strategic-inflection-point-creation-2508/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-15</td><td>0.20</td><td></td><td>Management changes</td><td>0.20 GPT4 / 0.30 local feel              __   BHC.TO __    -> i:0.2<-                      <br><br>FEELING: 0.2 --- <br> - Paulson's increased stake (19.13%) and Icahn's exit signal a potential shift in strategy for Bausch Health. Investors should monitor Paulson's influence and the company's future direction, particularly regarding the Bausch + Lomb subsidiary. <br><br>*** REZUMAT *** - Paulson Capital increased ownership of Bausch Health (BHC) common shares. - Paulson acquired Icahn's net long position of 34,721,118 shares. - Paulson now owns approximately 19.13% of Bausch Health's outstanding shares. - Director Appointment Agreement with Icahn Group terminated. - Brett M. Icahn and Steven D. Miller resigned from the Board. - Paulson expresses confidence in Bausch Health's value and prospects.   <br> <br>-- GPT4: 0.2, Hold, Paulson's stake increase may stabilize BHC; watch strategic shifts.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-16 14:07:44)</td><td><a href='https://www.tipranks.com/news/the-fly/paulson-increases-ownership-of-bausch-health-common-shares-thefly?mod=mw_quote_news' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-15</td><td>0.30</td><td></td><td>Management changes</td><td>0.30 GPT4 / 0.30 local feel              __   BHC.TO __    -> i:0.3<-                      <br><br>FEELING: 0.3 --- <br> - Paulson's significant stake increase (19.13%) following the acquisition of Icahn's position signals strong confidence in Bausch Health's value and future prospects. Investors should monitor board changes and Paulson's influence on the company's strategy. <br><br>*** REZUMAT *** - Paulson Capital Inc. now owns 19.13% of Bausch Health. - Acquisition of Icahn Group's 34,721,118 common shares. - Icahn Group's Director Appointment and Nomination Agreement terminated. - Brett M. Icahn and Steven D. Miller resigned from the Board. - Paulson expresses confidence in Bausch Health's value and prospects. - Bausch Health operates in pharmaceuticals, eye health, and related sectors. - Date of announcement: August 15, 2025.   <br> <br>-- GPT4: +0.3, Hold, Paulson's stake increase signals confidence; monitor strategic influence.   (GPT4o +++ gemma3:12b-it-q4_K_M on 2025-08-16 14:45:58)</td><td><a href='https://www.stocktitan.net/news/BHC/bausch-health-announces-increase-in-shareholding-by-its-chairperson-49o0u9ct46nw.html' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-08-15</td><td>0.20</td><td></td><td>nan</td><td>0.2 local feel              __   BHC.TO __    -> i:0.2<-                      <br><br>FEELING: total score 0.2 Reasoning: The news highlights revenue growth and a focus on AI-driven cybersecurity solutions. This falls under "product launches" and "adapting to evolving cybersecurity landscape," which suggests a positive outlook. The focus on AI and cybersecurity is a forward-looking element, indicating potential for continued growth. While the cookie usage mention is irrelevant to the financial assessment, the overall tone is cautiously optimistic. The score reflects this positive, but not overwhelmingly impactful, development. --- <br> - NetScout's revenue growth and focus on AI-driven cybersecurity solutions are positive indicators. Investors may find the company's adaptation to evolving cyber threats appealing, suggesting potential for continued growth. <br><br>*** REZUMAT *** - NetScout (NTCT) reported revenue growth. - Focus on AI to combat cyber threats. - Adapting to evolving cybersecurity landscape. - Utilizing cookies for website functionality and analytics. - Investors should consider NTCT's growth potential.   (gemma3:12b-it-q4_K_M on 2025-08-16 00:40:02)</td><td><a href='https://news.futunn.com/en/post/60693205/netscout-ntct-boosts-revenue-embraces-ai-to-tackle-cyber-threats' target='_blank'>Link</a></td></tr></table></div></div>
    </div>
    </body>
    </html>
    